

PU4870USw

Remarks

Currently Claims 1-32, 43-44 and 46 are pending. Claim 45 is canceled.

New claim 46 is added, support for which can be found throughout Applicants specification, including at page 15, line 16-17, page 17, line 22-29, page 18, lines 26-29, page 19, lines 1-3 and 18-20, page 20, lines 11, 16 and 20, page 21, line 9, page 22, lines 13-19, page 23, lines 20, 24 and 30, page 24, line 1, page 25, lines 15-16, page 26, lines 5-6, and original claim 1. No new matter is added.

The specification has been amended to correct an obvious clerical error on page 5 from subscript (R_2) to superscript (R^2). The remaining amendments correct obvious clerical errors in the formulas, to recite implicit H atoms (e.g., -N to -NH₂, and -O to -OH). No new matter is added.

The Examiner's attention is respectfully directed toward the definitions of the terms used in this application, which appear on pages 9-12 of the original specification, e.g., the term "alkyl" is defined as to include both unsubstituted alkyl and alkyl optionally substituted with 1 or more halogen atoms.

Entry of the foregoing amendments is respectfully requested.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 26 Apr 2006
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
Lorie.A.Morgan@gsk.com